Investors

investor-photo2

Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and immunological diseases. Enanta’s research and development efforts include programs in the following disease areas: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19) and hepatitis B Virus (HBV) and chronic spontaneous urticaria (CSU).

Learn More »

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

September 3, 2024
Enanta Pharmaceuticals to Participate in Investor Conferences in September
August 5, 2024
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Upcoming Events